Toleranzia AB (TOL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Toleranzia AB (TOL) has a cash flow conversion efficiency ratio of -0.023x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.98 Million ≈ $-428.10K USD) by net assets (Skr173.87 Million ≈ $18.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Toleranzia AB balance sheet independence to measure how much of total assets are equity-financed.
Toleranzia AB - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Toleranzia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Toleranzia AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Toleranzia AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Toleranzia AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wooree E&L Co. Ltd
KQ:153490
|
0.032x |
|
Atta Global Group Bhd
KLSE:7099
|
-0.008x |
|
Logisys Inc
KQ:067730
|
0.025x |
|
Capital Engineering Network Public Company Limited
BK:CEN
|
0.024x |
|
Vision Sigma
TA:VISN
|
-0.017x |
|
Astral Asia Bhd
KLSE:7054
|
0.003x |
|
Javelin Minerals Ltd
AU:JAV
|
-0.059x |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
-1.155x |
Annual Cash Flow Conversion Efficiency for Toleranzia AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of Toleranzia AB from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see TOL market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr180.07 Million ≈ $19.38 Million |
Skr-10.28 Million ≈ $-1.11 Million |
-0.057x | -38.60% |
| 2023-12-31 | Skr153.52 Million ≈ $16.52 Million |
Skr-6.32 Million ≈ $-680.46K |
-0.041x | +31.64% |
| 2022-12-31 | Skr119.51 Million ≈ $12.86 Million |
Skr-7.20 Million ≈ $-774.83K |
-0.060x | -12.56% |
| 2021-12-31 | Skr127.97 Million ≈ $13.77 Million |
Skr-6.85 Million ≈ $-737.10K |
-0.054x | +8.91% |
| 2020-12-31 | Skr67.92 Million ≈ $7.31 Million |
Skr-3.99 Million ≈ $-429.53K |
-0.059x | +53.62% |
| 2019-12-31 | Skr34.99 Million ≈ $3.77 Million |
Skr-4.43 Million ≈ $-477.06K |
-0.127x | +27.53% |
| 2018-12-31 | Skr27.59 Million ≈ $2.97 Million |
Skr-4.82 Million ≈ $-519.03K |
-0.175x | +54.26% |
| 2017-12-31 | Skr14.67 Million ≈ $1.58 Million |
Skr-5.61 Million ≈ $-603.27K |
-0.382x | -46.00% |
| 2016-12-31 | Skr20.06 Million ≈ $2.16 Million |
Skr-5.25 Million ≈ $-565.11K |
-0.262x | -90.44% |
| 2015-12-31 | Skr24.45 Million ≈ $2.63 Million |
Skr-3.36 Million ≈ $-361.73K |
-0.137x | +74.75% |
| 2014-12-31 | Skr1.72 Million ≈ $184.88K |
Skr-935.22K ≈ $-100.65K |
-0.544x | -- |
About Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more